Delivering advanced OCT, fundus imaging, and optical biometry systems to support accurate diagnostics and efficient workflows for eye care professionals worldwide SINGAPORE, SG / ACCESS Newswire / ...

The adrenergic antagonist improved near vision in adults with presbyopia, with over 20 hours of improvement from a single administration in the VEGA-3 trial.

LTS LOHMANN Therapie-Systeme AG ("LTS"), a leading pharmaceutical technology company specializing in advanced drug delivery systems, today announced the expansion of its service portfolio to include ...

SEATTLE--(BUSINESS WIRE)--Visus Therapeutics Inc., a clinical-stage pharmaceutical company focused on developing innovative ophthalmic therapies to improve vision for people around the world, today ...

In 2026, the biggest drivers of market trends in ophthalmology include rare diseases as well as gene therapies and AI, ...

Former Novartis subsidiary Alcon, after targeting the pharmaceutical eye drop scene with a trio of recent drug purchases, is adding another pair of arrows to its ophthalmic quiver. And this time, the ...

DUBLIN--(BUSINESS WIRE)--The "Ophthalmic Drugs Market Report 2025-2035" has been added to ResearchAndMarkets.com's offering. World revenue for the ophthalmic drugs market, in terms of value, is ...

Credit: Alcon. The active ingredient in Tryptyr is acoltremon, an agonist of transient receptor potential melastatin 8 thermoreceptors. Tryptyr significantly improved tear production compared with ...

Eyecelerator, a partner of the American Academy of Ophthalmology, is self-described as having the goal of advancing eye care ...